Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOY8VA)

Drug Name

AL002 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Triggering receptor expressed on monocytes 2 (TREM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DNL919	DMDFQLZ	Alzheimer disease	8A20	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Triggering receptor expressed on monocytes 2 (TREM2)	TTQRMSJ	TREM2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04592874) A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.
2	Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med. 2020 Sep 7;217(9):e20200785.
3	Clinical pipeline report, company report or official report of Denali